[go: up one dir, main page]

HRP20171999T1 - Novi derivati aminopirimidina - Google Patents

Novi derivati aminopirimidina Download PDF

Info

Publication number
HRP20171999T1
HRP20171999T1 HRP20171999TT HRP20171999T HRP20171999T1 HR P20171999 T1 HRP20171999 T1 HR P20171999T1 HR P20171999T T HRP20171999T T HR P20171999TT HR P20171999 T HRP20171999 T HR P20171999T HR P20171999 T1 HRP20171999 T1 HR P20171999T1
Authority
HR
Croatia
Prior art keywords
alkyl
optionally substituted
halogen
hydrogen
cyclopropyl
Prior art date
Application number
HRP20171999TT
Other languages
English (en)
Inventor
Daniela Angst
François GESSIER
Anna Vulpetti
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20171999T1 publication Critical patent/HRP20171999T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Claims (14)

1. Spoj, naznačen time, da ima sljedeću Formulu (I), ili njegova farmaceutski prihvatljiva sol: [image] (I) u kojoj, R1 je vodik, C1-C6 alkil prema potrebi supstituiran s hidroksi; R2 je vodik ili halogen; R3 je vodik ili halogen; R4 je vodik; R5 je vodik ili halogen; ili su R4 i R5 zajedno priključeni te predstavljaju vezu, -CH2-, -CH2-CH2- , -CH=CH-, -CH=CH-CH2-; -CH2-CH=CH-; ili -CH2-CH2-CH2-; R6 i R7 međusobno neovisno predstavljaju H, C1-C6 alkil prema potrebi supstituiran s hidroksilom, C3-C6 cikloalkil prema potrebi supstituiran s halogenom ili hidroksi, ili halogen; R8, R9, R, R’, R10 i R11 međusobno neovisno predstavljaju H, ili C1-C6 alkil prema potrebi supstituiran sa C1-C6 alkoksi; ili bilo koja dva od R8, R9, R, R’, R10 i R11 zajedno s atomom ugljika na kojega su vezani, mogu tvoriti 3-člani do 6-člani zasićeni karbociklički prsten; R12 je vodik ili C1-C6 alkil prema potrebi supstituiran s halogenom ili C1-C6 alkoksi; ili R12 i bilo koji od R8, R9, R, R’, R10 ili R11 zajedno s atomima na koje su vezani, mogu tvoriti 4-, 5-, 6- ili 7-člani azaciklički prsten, pri čemu taj prsten može prema potrebi biti supstituiran sa sljedećima: halogen, cijano, hidroksil, C1-C6 alkil ili C1-C6 alkoksi; n je 0 ili 1; i R13 je C2-C6 alkenil prema potrebi supstituiran sa sljedećima: C1-C6 alkil, C1-C6 alkoksi ili N,N-di-C1-C6 alkilamino; C2-C6 alkinil prema potrebi supstituiran sa sljedećima: C1-C6 alkil ili C1-C6 alkoksi; ili C2-C6 alkileniloksid prema potrebi supstituiran sa C1-C6 alkilom.
2. Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen/a time, da: R1 je vodik, ili C1-C6 alkil prema potrebi supstituiran s hidroksi; R2 je halogen; R3 je vodik; R4 je vodik; R5 je halogen; ili su R4 i R5 priključeni zajedno i predstavljaju vezu, -CH2-, -CH2-CH2- , -CH=CH-, -CH=CH-CH2-; -CH2-CH=CH-; ili -CH2-CH2-CH2-; R6 i R7 međusobno neovisno predstavljaju H, C1-C6 alkil prema potrebi supstituiran s hidroksilom, C3-C6 cikloalkil prema potrebi supstituiran s halogenom ili hidroksi, ili halogen; R8, R9, R10 i R11 međusobno neovisno predstavljaju H, ili C1-C6 alkil; ili bilo koja dva od R8, R9, R10 i R11 zajedno s atomom ugljika na kojega su vezani, mogu tvoriti 3-člani do 6-člani zasićeni karbociklički prsten; R i R’ su vodik; R12 je vodik ili C1-C6 alkil prema potrebi supstituiran s halogenom; ili R12 i bilo koji od R8, R9, R, R’, R10 ili R11 zajedno s atomima na koje su vezani, mogu tvoriti 4-, 5-, 6- ili 7-člani azaciklički prsten, pri čemu taj prsten može prema potrebi biti supstituiran sa sljedećima: halogen, cijano, hidroksil, C1-C6 alkil ili C1-C6 alkoksi; n je 0 ili 1; i R13 je C2-C6 alkenil prema potrebi supstituiran sa C1-C6 alkilom ili C1-C6 alkoksi; C2-C6 alkinil prema potrebi supstituiran sa C1-C6 alkilom ili C1-C6 alkoksi; ili C2-C6 alkileniloksid prema potrebi supstituiran sa C1-C6 alkilom.
3. Spoj prema zahtjevu 1 ili 2, ili njegova farmaceutski prihvatljiva sol, naznačen/a time, da: R1 je vodik, ili C1-C6 alkil prema potrebi supstituiran s hidroksi; R2 je halogen; R3 je vodik; R4 je vodik; R5 je halogen; R6 i R7 međusobno neovisno predstavljaju H, C1-C6 alkil prema potrebi supstituiran s hidroksilom, C3-C6 cikloalkil prema potrebi supstituiran s halogenom ili hidroksi, ili halogen; R8, R9, R10 i R11 međusobno neovisno predstavljaju H, ili C1-C6 alkil; ili bilo koja dva od R8, R9, R10 i R11 zajedno s atomom ugljika na kojega su vezani, mogu tvoriti 3-člani do 6-člani zasićeni karbociklički prsten; R i R’ su vodik; R12 je vodik ili C1-C6 alkil prema potrebi supstituiran s halogenom; ili R12 i bilo koji od R8, R9, R, R’, R10 ili R11 zajedno s atomima na koje su vezani, mogu tvoriti 4-, 5-, 6- ili 7-člani azaciklički prsten, pri čemu taj prsten može prema potrebi biti supstituiran sa sljedećima: halogen, cijano, hidroksil, C1-C6 alkil ili C1-C6 alkoksi; n je 0 ili 1; i R13 je C2-C6 alkenil prema potrebi supstituiran sa C1-C6 alkilom ili C1-C6 alkoksi; C2-C6 alkinil prema potrebi supstituiran sa C1-C6 alkilom ili C1-C6 alkoksi; ili C2-C6 alkileniloksid prema potrebi supstituiran sa C1-C6 alkilom.
4. Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen/a time, da: R1 je vodik, ili C1-C6 alkil prema potrebi supstituiran s hidroksi; R2 je vodik ili halogen; R3 je vodik ili halogen; R4 i R5 su priključeni zajedno i predstavljaju vezu, -CH2-, -CH2-CH2- , -CH=CH-, -CH=CH-CH2-; -CH2-CH=CH-; ili -CH2-CH2-CH2-; R6 i R7 međusobno neovisno predstavljaju H, C1-C6 alkil prema potrebi supstituiran s hidroksilom, C3-C6 cikloalkil prema potrebi supstituiran s halogenom ili hidroksi, ili halogen; R8, R9, R10 i R11 međusobno neovisno predstavljaju H, ili C1-C6 alkil; ili bilo koja dva od R8, R9, R10 i R11 zajedno s atomom ugljika na kojega su vezani, mogu tvoriti 3-člani do 6-člani zasićeni karbociklički prsten; R i R’ su vodik; R12 je vodik ili C1-C6 alkil prema potrebi supstituiran s halogenom; ili R12 i bilo koji od R8, R9, R, R’, R10 ili R11 zajedno s atomima na koje su vezani, mogu tvoriti 4-, 5-, 6- ili 7-člani azaciklički prsten, pri čemu taj prsten može prema potrebi biti supstituiran sa sljedećima: halogen, cijano, hidroksil, C1-C6 alkil ili C1-C6 alkoksi; n je 0 ili 1; i R13 je C2-C6 alkenil prema potrebi supstituiran sa C1-C6 alkilom ili C1-C6 alkoksi; C2-C6 alkinil prema potrebi supstituiran sa C1-C6 alkilom ili C1-C6 alkoksi; ili C2-C6 alkileniloksid prema potrebi supstituiran sa C1-C6 alkilom.
5. Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen/a time, da: R1 je vodik, ili C1-C6 alkil prema potrebi supstituiran s hidroksi; R2 je vodik ili halogen; R3 je vodik ili halogen; R4 i R5 su priključeni zajedno i predstavljaju -CH2-CH2- , ili -CH=CH-; R6 i R7 međusobno neovisno predstavljaju H, C1-C6 alkil prema potrebi supstituiran s hidroksilom, C3-C6 cikloalkil prema potrebi supstituiran s halogenom ili hidroksi, ili halogen; R8, R9, R10 i R11 međusobno neovisno predstavljaju H, ili C1-C6 alkil; ili bilo koja dva od R8, R9, R10 i R11 zajedno s atomom ugljika na kojega su vezani, mogu tvoriti 3-člani do 6-člani zasićeni karbociklički prsten; R i R’ su vodik; R12 je vodik ili C1-C6 alkil prema potrebi supstituiran s halogenom; ili R12 i bilo koji od R8, R9, R, R’, R10 ili R11 zajedno s atomima na koje su vezani, mogu tvoriti 4-, 5-, 6- ili 7-člani azaciklički prsten, pri čemu taj prsten može prema potrebi biti supstituiran sa sljedećima: halogen, cijano, hidroksil, C1-C6 alkil ili C1-C6 alkoksi; n je 0 ili 1; i R13 je C2-C6 alkenil prema potrebi supstituiran sa C1-C6 alkilom ili C1-C6 alkoksi; C2-C6 alkinil prema potrebi supstituiran sa C1-C6 alkilom ili C1-C6 alkoksi; ili C2-C6 alkileniloksid prema potrebi supstituiran sa C1-C6 alkilom.
6. Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen/a time, da: R1 je vodik, ili C1-C6 alkil prema potrebi supstituiran s hidroksi; R2 je halogen; R3 je vodik; R4 je vodik; R5 je halogen; R6 i R7 međusobno neovisno predstavljaju H, C1-C6 alkil prema potrebi supstituiran s hidroksilom, C3-C6 cikloalkil prema potrebi supstituiran s halogenom ili hidroksi, ili halogen; R8, R9, R10 i R11 međusobno neovisno predstavljaju H, ili C1-C6 alkil; R i R’ su vodik; R12 je vodik ili C1-C6 alkil prema potrebi supstituiran s halogenom; n je 0 ili 1; i R13 je C2-C6 alkenil prema potrebi supstituiran sa C1-C6 alkilom ili C1-C6 alkoksi; C2-C6 alkinil prema potrebi supstituiran sa C1-C6 alkilom ili C1-C6 alkoksi; ili C2-C6 alkileniloksid prema potrebi supstituiran sa C1-C6 alkilom.
7. Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen/a time, da: R1 je vodik, ili C1-C6 alkil prema potrebi supstituiran s hidroksi; R2 je halogen; R3 je vodik; R4 je vodik; R5 je halogen; R6 i R7 međusobno neovisno predstavljaju H, C1-C6 alkil prema potrebi supstituiran s hidroksilom, C3-C6 cikloalkil prema potrebi supstituiran s halogenom ili hidroksi, ili halogen; R8 i R9 međusobno neovisno predstavljaju H, ili C1-C6 alkil; R i R’ su vodik; R12 i bilo koji od R10 ili R11 zajedno s atomima na koje su vezani, mogu tvoriti 4-, 5-, 6- ili 7-člani azaciklički prsten, pri čemu taj prsten može biti prema potrebi supstituiran sa sljedećima: halogen, cijano, hidroksil, C1-C6 alkil ili C1-C6 alkoksi; n je 0 ili 1; i R13 je C2-C6 alkenil prema potrebi supstituiran sa C1-C6 alkilom ili C1-C6 alkoksi; C2-C6 alkinil prema potrebi supstituiran sa C1-C6 alkilom ili C1-C6 alkoksi; ili C2-C6 alkileniloksid prema potrebi supstituiran sa C1-C6 alkilom.
8. Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen/a time, da: R1 je vodik, ili C1-C6 alkil prema potrebi supstituiran s hidroksi; R2 je halogen; R3 je vodik; R4 je vodik; R5 je halogen; R6 i R7 međusobno neovisno predstavljaju H, C1-C6 alkil prema potrebi supstituiran s hidroksilom, C3-C6 cikloalkil prema potrebi supstituiran s halogenom ili hidroksi, ili halogen; R8, R9, R10 i R11 međusobno neovisno predstavljaju H, ili C1-C6 alkil; R i R’ su vodik; R12 je vodik ili C1-C6 alkil prema potrebi supstituiran s halogenom; n je 0 ili 1; i R13 je C2-C6 alkenil prema potrebi supstituiran sa C1-C6 alkilom ili C1-C6 alkoksi.
9. Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen/a time, da: R1 je vodik, ili C1-C6 alkil prema potrebi supstituiran s hidroksi; R2 je fluor; R3 je vodik; R4 je vodik; R5 je halogen; R6 i R7 međusobno neovisno predstavljaju H, C1-C6 alkil prema potrebi supstituiran s hidroksilom, C3-C6 cikloalkil prema potrebi supstituiran s halogenom ili hidroksi, ili halogen; R8 i R9 međusobno neovisno predstavljaju H, ili C1-C6 alkil; R12 i bilo koji od R10 ili R11 zajedno s atomima na koje su vezani, mogu tvoriti 4-, 5-, 6- ili 7-člani azaciklički prsten, pri čemu taj prsten može biti prema potrebi supstituiran sa sljedećima: halogen, cijano, hidroksil, C1-C6 alkil ili C1-C6 alkoksi; n je 0; i R13 je C2-C6 alkenil prema potrebi supstituiran sa C1-C6 alkilom ili C1-C6 alkoksi; ili C2-C6 alkinil prema potrebi supstituiran sa C1-C6 alkilom ili C1-C6 alkoksi.
10. Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen/a time, da: R1 je C1-C6 alkil; R2 je fluor; R3 je vodik; R4 je vodik; R5 je fluor; R6 i R7 međusobno neovisno predstavljaju H, C3-C6 cikloalkil ili halogen; R8, R9, R10 i R11 predstavljaju H; R12 je vodik; n je 0; i R13 je C2-C6 alkenil prema potrebi supstituiran sa C1-C6 alkilom.
11. Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen/a time, da : je odabran/a od sljedećih: N-(3-(5-((1-akriloilazetidin-3-il)oksi)-6-aminopirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; (E)-N-(3-(6-amino-5-((1-(but-2-enoil)azetidin-3-il)oksi)pirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; N-(3-(6-amino-5-((1-propioloilazetidin-3-il)oksi)pirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; N-(3-(6-amino-5-((1-(but-2-inoil)azetidin-3-il)oksi)pirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; N-(3-(5-((1-akriloilpiperidin-4-il)oksi)-6-aminopirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; N-(3-(6-amino-5-(2-(N-metilakrilamido)etoksi)pirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; (E)-N-(3-(6-amino-5-(2-(N-metilbut-2-enamido)etoksi)pirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; N-(3-(6-amino-5-(2-(N-metilpropiolamido)etoksi)pirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; (E)-N-(3-(6-amino-5-(2-(4-metoksi-N-metilbut-2-enamido)etoksi)pirimidin-4-il)-5-fluoro- 2-metilfenil)-4-ciklopropil-2-fluorobenzamid; N-(3-(6-amino-5-(2-(N-metilbut-2-inamido)etoksi)pirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; N-(2-((4-amino-6-(3-(4-ciklopropil-2-fluorobenzamido)-5-fluoro-2-metilfenil)pirimidin-5-il)oksi)etil)-N-metiloksiran-2-karboksamid; N-(2-((4-amino-6-(3-(6-ciklopropil-8-fluoro-1-oksoizokinolin-2(1H)-il)fenil)pirimidin-5-il)oksi)etil)-N-metilakrilamid; N-(3-(5-(2-akrilamidoetoksi)-6-aminopirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; N-(3-(6-amino-5-(2-(N-etilakrilamido)etoksi)pirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; N-(3-(6-amino-5-(2-(N-(2-fluoroetil)akrilamido)etoksi)pirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; N-(3-(5-((1-akrilamidociklopropil)metoksi)-6-aminopirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; (S)-N-(3-(5-(2-akrilamidopropoksi)-6-aminopirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; (S)-N-(3-(6-amino-5-(2-(but-2-inamido)propoksi)pirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; (S)-N-(3-(6-amino-5-(2-(N-metilakrilamido)propoksi)pirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; (S)-N-(3-(6-amino-5-(2-(N-metilbut-2-inamido)propoksi)pirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; N-(3-(6-amino-5-(3-(N-metilakrilamido)propoksi)pirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; (S)-N-(3-(5-((1-akriloilpirolidin-2-il)metoksi)-6-aminopirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; (S)-N-(3-(6-amino-5-((1-(but-2-inoil)pirolidin-2-il)metoksi)pirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; (S)-2-(3-(5-((1-akriloilpirolidin-2-il)metoksi)-6-aminopirimidin-4-il)-5-fluoro-2-(hidroksimetil)fenil)-6-ciklopropil-3,4-dihidroizokinolin-1(2H)-on; N-(2-((4-amino-6-(3-(6-ciklopropil-1-okso-3,4-dihidroizokinolin-2(1H)-il)-5-fluoro-2-(hidroksimetil)fenil)pirimidin-5-il)oksi)etil)-N-metilakrilamid; N-(3-(5-(((2S,4R)-1-akriloil-4-metoksipirolidin-2-il)metoksi)-6-aminopirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; N-(3-(6-amino-5-(((2S,4R)-1-(but-2-inoil)-4-metoksipirolidin-2-il)metoksi)pirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; 2-(3-(5-(((2S,4R)-1-akriloil-4-metoksipirolidin-2-il)metoksi)-6-aminopirimidin-4-il)-5-fluoro-2-(hidroksimetil)fenil)-6-ciklopropil-3,4-dihidroizokinolin-1(2H)-on; N-(3-(5-(((2S,4S)-1-akriloil-4-metoksipirolidin-2-il)metoksi)-6-aminopirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; N-(3-(6-amino-5-(((2S,4S)-1-(but-2-inoil)-4-metoksipirolidin-2-il)metoksi)pirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; N-(3-(5-(((2S,4R)-1-akriloil-4-fluoropirolidin-2-il)metoksi)-6-aminopirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; N-(3-(6-amino-5-(((2S,4R)-1-(but-2-inoil)-4-fluoropirolidin-2-il)metoksi)pirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; (S)-N-(3-(5-((1-akriloilazetidin-2-il)metoksi)-6-aminopirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; (S)-N-(3-(6-amino-5-((1-propioloilazetidin-2-il)metoksi)pirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; (S)-2-(3-(5-((1-akriloilazetidin-2-il)metoksi)-6-aminopirimidin-4-il)-5-fluoro-2-(hidroksimetil)fenil)-6-ciklopropil-3,4-dihidroizokinolin-1(2H)-on; (R)-N-(3-(5-((1-akriloilazetidin-2-il)metoksi)-6-aminopirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; (R)-N-(3-(5-((1-akriloilpiperidin-3-il)metoksi)-6-aminopirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; N-(3-(5-(((2R,3S)-1-akriloil-3-metoksipirolidin-2-il)metoksi)-6-aminopirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; N-(3-(5-(((2S,4R)-1-akriloil-4-cijanopirolidin-2-il)metoksi)-6-aminopirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; i N-(3-(5-(((2S,4S)-1-akriloil-4-cijanopirolidin-2-il)metoksi)-6-aminopirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid.
12. Farmaceutski sastav, naznačen time, da obuhvaća terapeutski učinkovitu količinu spoja prema bilo kojem od zahtjeva 1 do 11 te jedan ili više farmaceutski prihvatljivih nosača.
13. Kombinacija, naznačena time, da obuhvaća terapeutski učinkovitu količinu spoja prema bilo kojem od zahtjeva 1 do 11, ili njegove farmaceutski prihvatljive soli, te jedan ili više zajedničkih terapeutski djelotvornih sredstava.
14. Spoj prema bilo kojem od zahtjeva 1 do 11, ili njegova farmaceutski prihvatljiva sol, naznačen/a time, da se upotrebljava kao lijek.
HRP20171999TT 2013-11-29 2017-12-27 Novi derivati aminopirimidina HRP20171999T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13195081 2013-11-29
PCT/IB2014/066422 WO2015079417A1 (en) 2013-11-29 2014-11-28 Novel amino pyrimidine derivatives
EP14821285.5A EP3074386B1 (en) 2013-11-29 2014-11-28 Novel amino pyrimidine derivatives

Publications (1)

Publication Number Publication Date
HRP20171999T1 true HRP20171999T1 (hr) 2018-02-09

Family

ID=49674216

Family Applications (3)

Application Number Title Priority Date Filing Date
HRP20230585TT HRP20230585T1 (hr) 2013-11-29 2014-11-28 Novi derivati amino pirimidina
HRP20171999TT HRP20171999T1 (hr) 2013-11-29 2017-12-27 Novi derivati aminopirimidina
HRP20200775TT HRP20200775T1 (hr) 2013-11-29 2020-05-12 Novi derivati amino-pirimidina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20230585TT HRP20230585T1 (hr) 2013-11-29 2014-11-28 Novi derivati amino pirimidina

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20200775TT HRP20200775T1 (hr) 2013-11-29 2020-05-12 Novi derivati amino-pirimidina

Country Status (43)

Country Link
US (6) US9512084B2 (hr)
EP (4) EP3689865B1 (hr)
JP (2) JP6342495B2 (hr)
KR (2) KR102421388B1 (hr)
CN (2) CN105683181B (hr)
AP (1) AP2016009158A0 (hr)
AR (1) AR098549A1 (hr)
AU (1) AU2014356069B2 (hr)
BR (1) BR112016010397B1 (hr)
CA (1) CA2926908C (hr)
CL (1) CL2016001055A1 (hr)
CR (1) CR20160244A (hr)
CU (1) CU24384B1 (hr)
CY (3) CY1119705T1 (hr)
DK (3) DK3689865T3 (hr)
EA (1) EA031218B1 (hr)
EC (1) ECSP16054826A (hr)
ES (3) ES2655527T3 (hr)
FI (1) FI3689865T3 (hr)
HK (2) HK1223368A1 (hr)
HR (3) HRP20230585T1 (hr)
HU (3) HUE062248T2 (hr)
IL (1) IL244943B (hr)
JO (1) JO3314B1 (hr)
LT (3) LT3689865T (hr)
MA (1) MA39055B1 (hr)
MX (1) MX367911B (hr)
MY (2) MY179059A (hr)
NO (1) NO3074386T3 (hr)
NZ (1) NZ718835A (hr)
PE (1) PE20160869A1 (hr)
PH (1) PH12016500791A1 (hr)
PL (3) PL3299368T3 (hr)
PT (3) PT3074386T (hr)
RS (3) RS64275B1 (hr)
SI (3) SI3689865T1 (hr)
SV (1) SV2016005206A (hr)
TN (1) TN2016000128A1 (hr)
TW (1) TWI652261B (hr)
UA (1) UA117256C2 (hr)
UY (1) UY35858A (hr)
WO (1) WO2015079417A1 (hr)
ZA (1) ZA201602275B (hr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
PL3888674T3 (pl) 2014-04-07 2024-09-23 Novartis Ag Leczenie nowotworu złośliwego z zastosowaniem chimerycznego receptora antygenowego anty-CD19
EP3193915A1 (en) 2014-07-21 2017-07-26 Novartis AG Combinations of low, immune enhancing. doses of mtor inhibitors and cars
EP3172234B1 (en) 2014-07-21 2020-04-08 Novartis AG Treatment of cancer using a cd33 chimeric antigen receptor
WO2016014565A2 (en) 2014-07-21 2016-01-28 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
EP3660042B1 (en) 2014-07-31 2023-01-11 Novartis AG Subset-optimized chimeric antigen receptor-containing t-cells
JP6919118B2 (ja) 2014-08-14 2021-08-18 ノバルティス アーゲー ＧＦＲα−４キメラ抗原受容体を用いる癌の治療
RU2020117196A (ru) 2014-08-19 2020-10-15 Новартис Аг Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей
US10577417B2 (en) 2014-09-17 2020-03-03 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CN114107424A (zh) 2014-10-08 2022-03-01 诺华股份有限公司 预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途
CN107001478B (zh) 2014-10-14 2022-01-11 诺华股份有限公司 针对pd-l1的抗体分子及其用途
WO2016090034A2 (en) 2014-12-03 2016-06-09 Novartis Ag Methods for b cell preconditioning in car therapy
EP3280795B1 (en) * 2015-04-07 2021-03-24 Novartis AG Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
PL3280729T3 (pl) 2015-04-08 2022-08-22 Novartis Ag Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
ES2878188T3 (es) 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
CN108025051B (zh) 2015-07-29 2021-12-24 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
US20180371093A1 (en) 2015-12-17 2018-12-27 Novartis Ag Antibody molecules to pd-1 and uses thereof
CN109069597A (zh) 2015-12-22 2018-12-21 诺华股份有限公司 间皮素嵌合抗原受体(car)和抗pd-l1抗体抑制剂联用于抗癌治疗
SG11201807489PA (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
CN109641947B (zh) 2016-07-20 2023-04-14 犹他大学研究基金会 Cd229 car t细胞及其使用方法
AU2017341047B2 (en) 2016-10-07 2024-10-10 Novartis Ag Chimeric antigen receptors for the treatment of cancer
EP4279136A3 (en) 2016-12-03 2024-03-20 Juno Therapeutics, Inc. Methods for determining car-t cells dosing
WO2018201051A1 (en) 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
KR20200054160A (ko) 2017-06-02 2020-05-19 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 요법을 사용한 치료를 위한 물품 제조 및 방법
MX2019015155A (es) 2017-06-29 2020-08-03 Juno Therapeutics Inc Modelo de raton para valorar toxicidades asociadas con inmunoterapias.
PT3703750T (pt) 2017-11-01 2025-01-17 Memorial Sloan Kettering Cancer Center Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes
US12031975B2 (en) 2017-11-01 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
JP7256197B2 (ja) 2017-11-01 2023-04-11 ジュノー セラピューティクス インコーポレイテッド Ｂ細胞成熟抗原に特異的な抗体およびキメラ抗原受容体
AR113796A1 (es) * 2017-11-06 2020-06-10 Lilly Co Eli Compuestos inhibidores de tirosina cinasa de bruton (btk)
WO2019109053A1 (en) 2017-12-01 2019-06-06 Juno Therapeutics, Inc. Methods for dosing and for modulation of genetically engineered cells
CN108069911A (zh) * 2017-12-14 2018-05-25 中国药科大学 6－氨基－2－苯基嘧啶类化合物、制备方法和医药用途
EP3724225A1 (en) 2017-12-15 2020-10-21 Juno Therapeutics, Inc. Anti-cct5 binding molecules and methods of use thereof
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
US20210213063A1 (en) 2018-05-25 2021-07-15 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
SG11202011830SA (en) 2018-06-13 2020-12-30 Novartis Ag Bcma chimeric antigen receptors and uses thereof
CR20210045A (es) 2018-07-25 2021-06-18 Novartis Ag Inhibidores de inflamasoma nlrp3
AU2019374103A1 (en) 2018-11-01 2021-05-20 Juno Therapeutics, Inc. Chimeric antigen receptors specific for G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)
EP3873943A2 (en) 2018-11-01 2021-09-08 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
KR20210104713A (ko) 2018-11-16 2021-08-25 주노 쎄러퓨티크스 인코퍼레이티드 Ｂ 세포 악성 종양 치료를 위한 조작된 ｔ 세포 투약 방법
EP4427810A3 (en) 2018-11-30 2024-12-04 Juno Therapeutics, Inc. Methods for treatment using adoptive cell therapy
CA3123303A1 (en) 2019-01-29 2020-08-06 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
RS66195B1 (sr) 2019-05-23 2024-12-31 Novartis Ag Metode lečenja sjogrenovog sindroma pomoću inhibitora brutonove tirozin kinaze
MX2021014157A (es) 2019-05-23 2022-01-04 Novartis Ag Formas cristalinas de un inhibidor btk.
KR20220012281A (ko) 2019-05-23 2022-02-03 노파르티스 아게 브루톤 티로신 키나제 저해제를 이용하여 만성 자발성 두드러기를 치료하는 방법
WO2020234780A1 (en) 2019-05-23 2020-11-26 Novartis Ag Methods of treating asthma using a bruton's tyrosine kinase inhibitor
US20230121818A1 (en) 2019-12-23 2023-04-20 Biogen Ma Inc. Btk inhibitors
CN115916223A (zh) 2020-04-10 2023-04-04 朱诺治疗学股份有限公司 与用靶向b细胞成熟抗原的嵌合抗原受体工程化的细胞疗法相关的方法和用途
BR112023002031A2 (pt) 2020-08-14 2023-03-07 Novartis Ag Derivados de espiropiperidinila substituídos por heteroarila e usos farmacêuticos dos mesmos
WO2022033569A1 (zh) * 2020-08-14 2022-02-17 苏州晶云药物科技股份有限公司 苯甲酰胺类化合物的晶型及其制备方法
AU2022214490B2 (en) 2021-01-26 2025-01-02 Novartis Ag Pharmaceutical composition
WO2022212893A1 (en) 2021-04-02 2022-10-06 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
IL310975A (en) 2021-09-03 2024-04-01 Novartis Ag LOU064 for the treatment of multiple sclerosis
US20250032488A1 (en) 2021-12-14 2025-01-30 Novartis Ag Methods of treatment using lou064
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用ｌｏｕ０６４治療化膿性汗腺炎之方法
CN119546638A (zh) 2022-06-22 2025-02-28 朱诺治疗学股份有限公司 用于cd19靶向的car t细胞的二线疗法的治疗方法
US20240067627A1 (en) 2022-08-03 2024-02-29 Novartis Ag Nlrp3 inflammasome inhibitors
AU2023320568A1 (en) 2022-08-05 2025-02-06 Juno Therapeutics, Inc. Chimeric antigen receptors specific for gprc5d and bcma
WO2024069507A1 (en) 2022-09-30 2024-04-04 Novartis Ag Synthesis methods and intermediates for the production of remibrutinib
US20240226298A1 (en) 2022-12-13 2024-07-11 Juno Therapeutics, Inc. Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof
CN117024354B (zh) * 2023-10-08 2023-12-08 天津凯莱英制药有限公司 瑞米布替尼的制备方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
GB0005345D0 (en) 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
CA2426508A1 (en) 2000-10-23 2002-05-16 Bristol-Myers Squibb Company Modulators of bruton's tyrosine kinase and bruton's tyrosine kinase intermediates and methods for their identification and use in the treatment and prevention of osteoporosis and related disease states
ATE445613T1 (de) 2000-11-07 2009-10-15 Novartis Pharma Gmbh Indolylmaleimidderivative als proteinkinase-c- inhibitoren
AR036053A1 (es) 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
PE20040079A1 (es) 2002-04-03 2004-04-19 Novartis Ag Derivados de indolilmaleimida
CA2503330A1 (en) 2002-10-29 2004-05-13 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
BR0317099A (pt) 2002-12-09 2005-10-25 Boardd Of Regents Of The Unive Método in vitro para inibir a função e/ou proliferação de uma janus tirosina quinase 3, método de teste in vitro para auxiliar na identificação de substâncias que são úteis como imunossupressores terapêuticos, método in vitro para auxiliar na identificação de um novo medicamento imunossupressor, método in vitro para inibir a função e/ou proliferação de uma célula expressando a janus tirosina quinase 3, uso de pelo menos um composto, composto quìmico isolado ou purificado e composição farmacêutica
EP1473039A1 (en) 2003-05-02 2004-11-03 Centre National De La Recherche Scientifique (Cnrs) Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis
EP2644195A1 (en) 2003-05-19 2013-10-02 Irm Llc Immunosuppressant Compounds and Compositions
NZ546058A (en) 2004-01-12 2010-09-30 Ym Biosciences Australia Pty Benzimidazole and other fused ring derivatives as selective janus kinase inhibitors
TW200716551A (en) 2005-03-10 2007-05-01 Cgi Pharmaceuticals Inc Certain substituted amides, method of making, and method of use thereof
AR063946A1 (es) * 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
JP2010502751A (ja) 2006-09-11 2010-01-28 シージーアイ ファーマシューティカルズ，インコーポレイティド キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法
HUE025459T2 (hu) 2006-09-22 2016-05-30 Pharmacyclics Inc A Bruton-féle tirozin-kináz inhibitorai
EP2550976A3 (en) 2007-03-14 2013-04-03 Bionsil S.r.l. Modulator compounds of the drug resistance in epithelial tumour cells
EP2297105B1 (en) 2008-05-06 2015-09-02 Gilead Connecticut, Inc. Substituted amides, method of making, and use as btk inhibitors
CA2728683C (en) 2008-07-02 2017-05-02 F.Hoffmann-La Roche Ag Novel phenylpyrazinones as kinase inhibitors
CN102159214A (zh) 2008-07-16 2011-08-17 药品循环公司 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
US20100261776A1 (en) 2008-11-07 2010-10-14 The Research Foundation Of State University Of New York Bruton's tyrosine kinase as anti-cancer drug target
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
EP2421854B1 (en) 2009-04-24 2014-07-23 F.Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
UY33241A (es) * 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
MX2012009851A (es) * 2010-02-26 2012-09-12 Boehringer Ingelheim Int Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmaceuticas.
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
US8703767B2 (en) 2011-04-01 2014-04-22 University Of Utah Research Foundation Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors
BR112013029508B1 (pt) 2011-05-17 2022-05-03 Principia Biopharma, Inc. Composto, composição farmacêutica, e, uso do referido composto
SG194219A1 (en) 2011-06-10 2013-11-29 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
MX2014000130A (es) 2011-06-28 2014-05-01 Pharmacyclics Inc Procedimientos y composiciones para la inhibicion de resorcion osea.
US9233111B2 (en) 2011-07-08 2016-01-12 Novartis Ag Pyrrolo pyrimidine derivatives
US9273317B2 (en) 2011-08-09 2016-03-01 Fred Hutchinson Cancer Research Center Methods and compositions for inhibiting the growth and/or proliferation of MYC-driven tumor cells
KR102258778B1 (ko) 2011-10-19 2021-06-02 파마싸이클릭스 엘엘씨 브루톤 티로신 인산화효소(btk)의 억제제의 용도
WO2013063401A1 (en) 2011-10-28 2013-05-02 Celgene Avilomics Research, Inc. Methods of treating a bruton's tyrosine kinase disease or disorder
WO2013083666A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
IN2014MN01897A (hr) 2012-03-09 2015-07-10 Carna Biosciences Inc
CN104662018B (zh) 2012-04-20 2017-10-24 阿迪维纳斯治疗有限公司 取代的杂双环化合物、组合物及其医疗应用
WO2013157021A1 (en) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
WO2013173518A1 (en) 2012-05-16 2013-11-21 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
WO2014025976A1 (en) 2012-08-10 2014-02-13 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
EP3680238A1 (en) 2012-10-04 2020-07-15 University of Utah Research Foundation Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
US9512084B2 (en) * 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives

Also Published As

Publication number Publication date
DK3074386T3 (en) 2018-01-22
LT3074386T (lt) 2017-12-27
ES2655527T3 (es) 2018-02-20
SI3074386T1 (en) 2018-02-28
CN105683181B (zh) 2019-04-23
HK1252317A1 (zh) 2019-05-24
TWI652261B (zh) 2019-03-01
PH12016500791B1 (en) 2016-06-13
HRP20200775T1 (hr) 2020-07-24
KR20160088877A (ko) 2016-07-26
CN110172056A (zh) 2019-08-27
PE20160869A1 (es) 2016-09-08
EP3074386B1 (en) 2017-10-11
NZ718835A (en) 2021-12-24
NO3074386T3 (hr) 2018-03-10
US20150152068A1 (en) 2015-06-04
MA39055B1 (fr) 2018-10-31
LT3299368T (lt) 2020-05-25
PT3074386T (pt) 2017-11-15
JP6667573B2 (ja) 2020-03-18
CY1126056T1 (el) 2023-11-15
HUE049794T2 (hu) 2020-10-28
RS56657B1 (sr) 2018-03-30
CA2926908A1 (en) 2015-06-04
MX2016006908A (es) 2016-08-17
BR112016010397A8 (pt) 2020-04-22
KR20220044370A (ko) 2022-04-07
US20230312483A1 (en) 2023-10-05
MX367911B (es) 2019-09-11
EP4219478A1 (en) 2023-08-02
HRP20230585T1 (hr) 2023-09-01
CN110172056B (zh) 2022-04-19
KR102421388B1 (ko) 2022-07-18
JP2016538313A (ja) 2016-12-08
KR102380539B1 (ko) 2022-03-29
US11180460B2 (en) 2021-11-23
SV2016005206A (es) 2016-11-21
SI3299368T1 (sl) 2020-07-31
US10457647B2 (en) 2019-10-29
DK3689865T3 (en) 2023-06-19
CU24384B1 (es) 2019-03-04
AU2014356069A1 (en) 2016-05-05
JP2018141005A (ja) 2018-09-13
LT3689865T (lt) 2023-07-10
UA117256C2 (uk) 2018-07-10
AR098549A1 (es) 2016-06-01
PT3299368T (pt) 2020-05-28
MY191381A (en) 2022-06-22
CU20160078A7 (es) 2016-09-30
JP6342495B2 (ja) 2018-06-13
EP3299368B1 (en) 2020-02-26
PL3299368T3 (pl) 2020-08-10
AP2016009158A0 (en) 2016-04-30
US9512084B2 (en) 2016-12-06
CR20160244A (es) 2016-07-29
US20180251432A1 (en) 2018-09-06
CN105683181A (zh) 2016-06-15
PH12016500791A1 (en) 2016-06-13
US11673868B2 (en) 2023-06-13
FI3689865T3 (fi) 2023-06-12
RS64275B1 (sr) 2023-07-31
ECSP16054826A (es) 2017-10-31
EP3299368A1 (en) 2018-03-28
WO2015079417A1 (en) 2015-06-04
AU2014356069B2 (en) 2017-06-15
PL3074386T3 (pl) 2018-03-30
IL244943B (en) 2020-04-30
CA2926908C (en) 2021-10-26
EP3689865A1 (en) 2020-08-05
JO3314B1 (ar) 2019-03-13
BR112016010397B1 (pt) 2023-04-11
EA201691125A1 (ru) 2016-09-30
PL3689865T3 (pl) 2023-07-31
US20200010426A1 (en) 2020-01-09
DK3299368T3 (da) 2020-05-25
CY1122924T1 (el) 2021-10-29
ZA201602275B (en) 2017-08-30
US20160235746A1 (en) 2016-08-18
MY179059A (en) 2020-10-26
HUE062248T2 (hu) 2023-10-28
HK1223368A1 (zh) 2017-07-28
EP3689865B1 (en) 2023-03-29
RS60251B1 (sr) 2020-06-30
HUE037588T2 (hu) 2018-09-28
ES2791525T3 (es) 2020-11-04
TW201609666A (zh) 2016-03-16
EP3074386A1 (en) 2016-10-05
EA031218B1 (ru) 2018-12-28
ES2947770T3 (es) 2023-08-18
IL244943A0 (en) 2016-05-31
SI3689865T1 (sl) 2023-07-31
US20220041561A1 (en) 2022-02-10
MA39055A1 (fr) 2018-02-28
CL2016001055A1 (es) 2016-10-28
CY1119705T1 (el) 2018-06-27
UY35858A (es) 2015-06-30
TN2016000128A1 (en) 2017-10-06
PT3689865T (pt) 2023-06-16

Similar Documents

Publication Publication Date Title
HRP20171999T1 (hr) Novi derivati aminopirimidina
HRP20160002T1 (hr) Bicikliäśki heterocikliäśki spojevi kao inhibitori protein tirozin kinaze
JP2016538313A5 (hr)
HRP20171453T1 (hr) Derivati imidazotiadiazola i imidazopirazina kao inhibitori proteazom aktiviranog receptora 4 (par4) za liječenje agregacije trombocita
HRP20220255T1 (hr) Derivati 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f]izokinolina koji su korisni u liječenju raka
AR065556A1 (es) Derivados de 3-(( 1,2,4) triazolo (4,3-a) piridin -7-il) benzamida
AR083339A1 (es) Compuestos de quinazolina como bloqueadores de los canales de sodio
EA200800727A1 (ru) Введение ингибиторов дипептидилпептидазы
EA200970656A1 (ru) Вич-ингибирующие 5,6-замещенные пиримидины
HRP20160647T1 (hr) Novi heterociklički derivati i njihova uporaba u liječenju neuroloških poremećaja
EA200970655A1 (ru) 6-замещенные пиримидины, ингибирующие вич
HRP20160852T1 (hr) Biciklični heterociklični spojevi kao inhibitori protein tirozin kinaze
PE20141582A1 (es) Pirimidinas anilladas sustituidas y uso de las mismas
AR058703A1 (es) Triazolopiridazinas inhibidoras de tirosinquinasas, metodo de preparacion, composiciones farmaceuticas que las contienen y usos terapeuticos en el tratamiento del cancer
HRP20121069T1 (hr) Supstituirani derivati amida kao inhibitori protein kinaze
HRP20231048T1 (hr) Derivati bipirazola kao jak inhibitori
JP2016506962A5 (hr)
AR074426A1 (es) Compuesto de n-(((1s,4s,6s)-3-(2-piridinilcarbonil)3-azabiciclo (4,1.0)hept-4-il) metil)-2-heteroarilamina, su uso para la prepracion de un medicamento para el tratamiento de una enfermedad que requiere un antagonista de un receptor de orexina humana y composicion farmaceutica que lo comprende
PH12014502886A1 (en) NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS
PE20141228A1 (es) Derivados de pirrolopirimidina y purina
AR062503A1 (es) Derivados de pirido[2, 3-d]pirimidina y pirazin[2, 3-d]pirimidina, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de mtor.
AR074238A1 (es) Compuesto de n-{[(1r,4s,6r)-3-(2-piridinilcarbonil)-3-azabiciclo[4,1.0]hept-4-il]metil}-2-heteroarilamina, su uso para la preparacion de un medicamento util para el tratamiento de una enfermedad que requiere un antagonista del receptor de orexina humano y composicion farmaceutica que lo comprende
HRP20130984T1 (hr) Spoj aciltiouree ili njegove soli, i njegova primjena
NZ592238A (en) Pharmaceutical compositions comprising 4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine derivatives
SI2895174T1 (en) The prodrugs of the amino quinazoline kinase inhibitor